Our studies revealed the possible roles of WASF2 across cancer, demonstrating that WASF2 would be a potential candidate for clinical biomarker, which could be used as a potential diagnostic and prognostic biomarker in many cancers, especially in ovarian cancer. This evidence concerns the gene WASF2 and ovarian carcinoma.